PharmAthene (PIP) : Perkins Capital Management Inc reduced its stake in PharmAthene by 9.41% during the most recent quarter end. The investment management company now holds a total of 864,000 shares of PharmAthene which is valued at $2,185,920 after selling 89,800 shares in PharmAthene , the firm said in a disclosure report filed with the SEC on Jul 20, 2016.PharmAthene makes up approximately 2.40% of Perkins Capital Management Inc’s portfolio.
Other Hedge Funds, Including , Bnp Paribas Arbitrage Sa added PIP to its portfolio by purchasing 2,464 company shares during the most recent quarter which is valued at $6,135.
PharmAthene opened for trading at $2.51 and hit $2.56 on the upside on Wednesday, eventually ending the session at $2.56, with a gain of 1.59% or 0.04 points. The heightened volatility saw the trading volume jump to 1,87,641 shares. Company has a market cap of $168 M.
Pharmathene Inc. (Pharmathene) is a biodefense company. The Company is engaged in the development of medical counter measures against biological and chemical threats. The Company has several biodefense candidates in its portfolio: Anthrax vaccines including SparVax which is a second generation liquid recombinant protective antigen (rPA) anthrax vaccine and a lyophilized anthrax vaccine containing rPA; rBChE (recombinant butyrylcholinesterase) bioscavenger which is a medical counter measure for nerve agent poisoning by organophosphorous (OP) compounds including nerve gases and pesticides and Valortim which is a fully human monoclonal antibody for the prevention and treatment of anthrax infection. The Company develops Valortim in collaboration with Bristol-Myers Squibb (BMS).